On Oct 01, major Wall Street analysts update their ratings for $IGM Biosciences (IGMS.US)$, with price targets ranging from $9 to $48.
J.P. Morgan analyst Eric Joseph downgrades to a sell rating, and adjusts the target price from $12 to $9.
Jefferies analyst Roger Song maintains with a buy rating, and maintains the target price at $48.
Guggenheim analyst Michael Schmidt maintains with a buy rating, and sets the target price at $20.
Stifel analyst Stephen Willey maintains with a buy rating, and maintains the target price at $25.
RBC Capital analyst Brian Abrahams maintains with a buy rating, and adjusts the target price from $20 to $17.
Furthermore, according to the comprehensive report, the opinions of $IGM Biosciences (IGMS.US)$'s main analysts recently are as follows:
IGM Biosciences announced a shift in their pipeline focus, emphasizing their I&I candidates imvotamab and IGM-2644 while discontinuing the oncology asset aplitabart following an interim evaluation of a study for second-line metastatic renal cell carcinoma. Concurrent with this pipeline update, there was a significant turnover among the company's executive leadership. This alteration in strategy has led to a perceived reduction in potential catalysts for IGM's stock value in the mid-term, resulting in a view of an unfavorable risk/reward scenario at the current share price.
IGM Biosciences has decided to halt the advancement of aplitabart in oncology to pivot its attention towards autoimmune diseases exclusively. This strategic shift follows data from a recent trial in combination with FOLFIRI and bevacizumab for second-line metastatic colorectal cancer, which reached full enrollment earlier. Analysts maintain a positive outlook on bispecific T cell engagers for B cell-mediated autoimmune conditions and suggest that IgM bispecifics could offer superior safety and efficacy compared to IgG counterparts. Consequently, forecasts have been adjusted to exclude aplitabart, while incorporating projections for imvotamab in systemic lupus erythematosus due to the redirection of resources and focus.
Following IGM Biosciences' strategic shift to concentrate solely on autoimmune diseases, including halting the development of aplitabart in second-line mCRC and advancing imvotamab and IGM-2644 for autoimmune conditions, analysts perceive the discontinuation of aplitabart as a disappointment. However, it is not considered essential to the core investment narrative as it was deemed a high-risk initiative. The pipeline's recent realignment is seen positively and as a proper strategic decision.
The halting of aplitabart has been seen as a setback, yet IGM Biosciences' transition towards a dedicated autoimmune entity with a focus on T-cell engagers is expected to clarify their investment narrative, concentrate on the most promising sectors, and conserve resources. Despite a drop in the stock's post-market performance, it is perceived as an opportunity to invest before the release of significant autoimmune data related to imvotamab.
Here are the latest investment ratings and price targets for $IGM Biosciences (IGMS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月1日，多家華爾街大行更新了$IGM Biosciences (IGMS.US)$的評級，目標價介於9美元至48美元。
摩根大通分析師Eric Joseph下調至賣出評級，並將目標價從12美元下調至9美元。
富瑞集團分析師Roger Song維持買入評級，維持目標價48美元。
Guggenheim分析師Michael Schmidt維持買入評級，目標價20美元。
斯迪富分析師Stephen Willey維持買入評級，維持目標價25美元。
加皇資本市場分析師Brian Abrahams維持買入評級，並將目標價從20美元下調至17美元。
此外，綜合報道，$IGM Biosciences (IGMS.US)$近期主要分析師觀點如下：
IgM Biosciences宣佈轉變研發重點，強調其I&I候選藥物imvotamab和IgM-2644，同時在對一項二線轉移性腎細胞癌的研究進行中期評估後，停止了腫瘤資產aplitabart。在這次管道更新的同時，公司高管領導層的人員流失率也很高。這種戰略的改變導致IGM股票價值的潛在催化劑在中期內明顯減少，導致人們認爲當前股價的風險/回報情景不利。
IgM Biosciences已決定停止aplitabart在腫瘤學領域的發展，將其注意力完全集中在自身免疫性疾病上。這一戰略轉變是在最近一項與FOLFIRI和貝伐珠單抗聯合治療二線轉移性結直腸癌的試驗數據之後發生的，該試驗較早已達到滿員入組。分析師對治療b細胞介導的自身免疫性疾病的雙特異性T細胞參與劑保持樂觀展望，並認爲與IgG同行相比，IgM雙特異性可以提供更高的安全性和有效性。因此，由於資源和重點的重定向，對預測進行了調整，將aplitabart排除在系統性紅斑狼瘡中，同時納入了對imvotamab的預測。
繼IgM Biosciences的戰略轉向僅專注於自身免疫性疾病之後，包括停止二線mCRC中aplitabart的開發以及推進針對自身免疫性疾病的imvotamab和IgM-2644的開發，分析人士認爲停止使用aplitabart令人失望。但是，它被認爲是一項高風險舉措，因此不被認爲對核心投資敘述至關重要。該管道最近的調整被視爲積極的戰略決策。
aplitabart的停產被視爲挫折，但預計IgM Biosciences向專注於T細胞參與者的專門自身免疫實體的過渡將澄清他們的投資理念，專注於最有前途的行業，並節省資源。儘管該股的盤後表現有所下降，但在發佈與imvotamab相關的重要自身免疫數據之前，它被視爲投資的機會。
以下爲今日6位分析師對$IGM Biosciences (IGMS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
